Gabrielsen Discusses New State and Federal Efforts to Curb Prescription Opioid Abuse
February 8, 2018
Bloomberg BNA Health Law Resource Center
Associate Lindsey Gabrielsen is quoted in a Bloomberg BNA Health Law Resource Center article, “Doctors Feel the Pinch of Anti-Opioid Efforts,” about doctors’ efforts to comply with new state and federal limits on prescribing opioids.
Gabrielsen said the new limits can trip up physicians who don’t keep careful track of their prescribing history. “These government initiatives use data mining and data sharing to identify and target those physicians who prescribe more opioids than their peers, making them potential targets for government investigation,” she said.
She said doctors can take a number of practical steps to manage their opioid prescription risks, including taking the time to understand their state’s opioid prescribing laws. Focusing on documentation compliance is critical, she added. “If the government issues an investigatory subpoena for records, prescribers must be able to produce complete patient records containing notes with patient history, examination, and prescription information,” she said.
Gabrielsen said the new limits can trip up physicians who don’t keep careful track of their prescribing history. “These government initiatives use data mining and data sharing to identify and target those physicians who prescribe more opioids than their peers, making them potential targets for government investigation,” she said.
She said doctors can take a number of practical steps to manage their opioid prescription risks, including taking the time to understand their state’s opioid prescribing laws. Focusing on documentation compliance is critical, she added. “If the government issues an investigatory subpoena for records, prescribers must be able to produce complete patient records containing notes with patient history, examination, and prescription information,” she said.
Related News
April 3, 2026
In the News
David Rosen Weighs in on FDA's Pharma PR Crackdown – 'Stick to the Data'
Foley & Lardner LLP partner David Rosen shared insights on the regulatory challenges pharmaceutical companies face when publicly communicating around new cancer therapies in the MM+M article, “When a podcast becomes promotion: Inside the FDA’s warning shot at ImmunityBio.”
April 2, 2026
In the News
Susan Poll Klaessy and Adrienne Walker Named Chair and Vice Chair of Foley’s Bankruptcy & Business Reorganizations Practice
Foley & Lardner LLP partner Susan Poll Klaessy was appointed chair of the firm’s global Bankruptcy & Business Reorganizations Practice Group. Partner Adrienne Walker will serve as vice chair, supporting the continued growth and strategic direction of the practice.
April 1, 2026
In the News
Foley Featured on Top 10 Sales of 2025 List by Golf Inc.
Foley & Lardner LLP advised on two transactions named among Golf Inc.’s Top 10 Sales of 2025.